News
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has ...
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
Al Jazeera on MSN7d
Wegovy maker Novo Nordisk warns of layoffs as competition grows
Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...
Danish pharmaceutical giant Novo Nordisk on Tuesday named its new CEO and cut its full-year sales and profit guidance.
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback